Clinical Trials Directory

Trials / Completed

CompletedNCT00005668

A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
96 (planned)
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma. Aspergilloma is a "fungal ball" in the lungs caused by Aspergillus. The infection can spread from the lungs through the blood to other organs. Aspergilloma can be life-threatening; therefore, an effective treatment is needed.

Detailed description

Patients are randomly selected to receive itraconazole oral solution by mouth or the inactive placebo (oral cyclodextrin solution) twice daily for 12 months.

Conditions

Interventions

TypeNameDescription
DRUGItraconazole oral solution

Timeline

Completion
2005-11-01
First posted
2001-08-31
Last updated
2010-08-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00005668. Inclusion in this directory is not an endorsement.

A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin (NCT00005668) · Clinical Trials Directory